Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s new suite of policies on the development of drugs targeted to neurological diseases — including #ALS and Alzheimer’s — adopts modern, efficient principles for advancing new medical innovation https://t.co/47niz5JjJk
SteveFDA (R-D.C.)
@SGottliebFDA
RT @BlumenthalG: to those who don't even bother reading through the discussion section: which therapies would you want to deny patients bas… QT @BlumenthalG: Table 1 shows many drugs granted AA based on RR that converted to RA based on PFS. Several of these (ALKi for ALK+… https://t.co/kKgrYEp9hV)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_ORA: NEW! #FDAORA works hard to keep your food, drugs, and more safe. Here’s what we accomplished in 2017:… https://t.co/cctO6MCYFZ
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: 25-year FDA review finds only a small number of oncology products granted accelerated approval fail to verify clini… https://t.co/kxm7vhyLmY
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: .@US_FDA Considers a Shift on #MedDevice Quality System Regulations | #Regulatory Focus https://t.co/CVE4btXaEv #FDA https://t.co/IrNNIJ8dlX
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA committed to working closely w/Congress to advance #RightToTry legislation that gives terminal patients chance to access promising treatments as part of our commitment to promote public health options. We're working closely with legislators; providin
SteveFDA (R-D.C.)
@SGottliebFDA
#RightToTry policies rooted in strong desire to help patients facing terminal illnesses access experimental therapies with hope they'll help. #FDA shares the administration’s goal to help patients facing terminal diagnosis access potentially promising tre
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: We continue to recommend getting the #flu vaccine to prevent flu. It’s true that flu vaccines often have lower effe… https://t.co/Q5jRnZYLG1
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RAPSorg: .@US_FDA Adds 35 New, 22 Revised Product-Specific Guidances for Generic Drugmakers | #Regulatory Focus… https://t.co/4BXySfmluI
SteveFDA (R-D.C.)
@SGottliebFDA
#Flu activity continues to increase across the U.S. Remember 3 steps to #fightflu: 1⃣ Get yourself & your family a flu shot 2⃣ Take everyday preventive actions 3⃣ Take antiviral drugs, if your doctor prescribes them https://t.co/6UrDYZ3wrd htt
SteveFDA (R-D.C.)
@SGottliebFDA
Watching the #SuperBowl this weekend? Try to avoid situations that can spread the flu — and remember especially, no double dipping! #FightFlu https://t.co/g7Ju1vPXND
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA Update: We recognize that managing the thousands of flu-related hospitalizations has increased demand for certain IV saline products used to both hydrate and deliver IV meds. We are continuing to take new steps to increase supply of IV fluids https:/
SteveFDA (R-D.C.)
@SGottliebFDA
About 3 out of 4 teens smokers will become adult smokers. We’re going to be taking new steps in 2018 to address adolescent and teen use of tobacco products https://t.co/o48I8OqGof https://t.co/FoazgXzycS
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA’s record number of novel 2017 approvals of drug and biologics (56); devices (95); and generics (1,027) was culmination of years of dedicated efforts by staff to modernize policies; a wave of scientific progress; and new legislation like Cures Act tha
SteveFDA (R-D.C.)
@SGottliebFDA
March 19 FDA workshop on Patient-Focused Drug Development: Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data https://t.co/gBffnNCrL6… #PFDD
SteveFDA (R-D.C.)
@SGottliebFDA
3/3 Americans MUST have confidence FDA acts quickly in setting of food recalls to protect them. This is the core of our consumer protection role. We’ve improved much; will prove it with updated data; and will make process even better in 2018. Wish everyon
SteveFDA (R-D.C.)
@SGottliebFDA
2/3 We made MANY processs improvements to speed food recalls; increase our rigor. We’ll release updated analysis - from 2017 NOT 2012 - on how we’re doing. More reforms in store for 2018; including changes to make sure we release much more info to consume
SteveFDA (R-D.C.)
@SGottliebFDA
1/2 This report, first released in 2016, was re-released over Christmas. It’s based on a selective review of 30 complex food recalls from 2012-2015 out of 1,000s performed. In many of the 30 FDA was slow to act. Even a few flawed recalls are too many. We QT @NYTHealth: Federal investigators say the F.D.A. must get tainted foods off the shelves faster to protect consumers from illness https://t.co/s0fP1NHuuL)